MedTrace Logo

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

NCT02449018 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)

Conditions

  • Chronic Obstructive Pulmonary Disease, COPD

Interventions

DRUG

QBW251

QBW251 capsule(s) taken orally twice per day

DRUG

Placebo

Matching placebo capsule(s) taken orally twice per day

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-12-27
Completion
2017-01-23
FDA Drug
Yes

Countries

  • United States
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02449018 on ClinicalTrials.gov